What is DxTerity?
DxTerity operates as a pioneering force in the field of RNA-based diagnostics, specifically targeting the complex landscape of autoimmune diseases. By integrating patented genomic technologies with accessible at-home monitoring, the company bridges the gap between clinical-grade precision and patient-centric healthcare. Their market position is defined by a dual focus on biological innovation and cost-efficiency, allowing healthcare providers to utilize sophisticated diagnostic tools that were previously inaccessible or prohibitively expensive. Through active participation in clinical studies and a commitment to longitudinal health tracking, DxTerity is effectively redefining the standard of care for chronic autoimmune conditions.
How much funding has DxTerity raised?
DxTerity has raised a total of $4.5M across 4 funding rounds:
Private Equity
$790K
Debt
$2.6M
Debt
$350K
Debt
$794K
Private Equity (2009): $790K, investors not publicly disclosed
Debt (2012): $2.6M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2021): $794K featuring PPP
Key Investors in DxTerity
PPP
Public-Private Partnership
Undisclosed Investor
A private equity participant focused on long-term value creation within the biotechnology and life sciences sectors.
Undisclosed Investor
A strategic financial partner providing capital to facilitate the advancement of proprietary genomic technologies and clinical diagnostic platforms.
What's next for DxTerity?
With the recent infusion of capital, DxTerity is poised to scale its clinical diagnostic infrastructure and expand its footprint in the precision medicine market. The strategic roadmap likely involves the commercialization of new genomic monitoring assays and the strengthening of its data analytics capabilities to better serve the autoimmune patient population. As the company transitions into this next phase of enterprise-level growth, the focus will remain on enhancing the accessibility of its diagnostic platform while maintaining the rigorous scientific standards required for clinical adoption. Future initiatives will likely prioritize the integration of their diagnostic insights into broader telehealth ecosystems, further cementing their role as a critical partner in modern, data-driven healthcare delivery.
See full DxTerity company page
